Immunic, Inc. (IMUX)

Immunic, Inc. (IMUX) Healthcare & Pipeline Overview

Immunic, Inc. is a clinical-stage biopharmaceutical company specializing in selective oral immunology therapies for chronic inflammatory and autoimmune diseases. Their lead candidate, IMU-838, targets conditions like multiple sclerosis and inflammatory bowel disease, positioning them in a competitive yet high-growth sector.

What Is the Investment Thesis for IMUX?

Immunic, Inc. presents a notable research candidate within the biotechnology sector, driven by its pipeline of oral immunology therapies targeting chronic inflammatory and autoimmune diseases. The company's lead candidate, IMU-838, currently in Phase 2 trials, addresses significant unmet needs in multiple sclerosis and inflammatory bowel disease. Successful trial outcomes could lead to substantial market penetration, given the convenience and potential tolerability advantages of oral therapies. Key value drivers include the advancement of IMU-838 through clinical trials, the expansion of its pipeline with IMU-935 and IMU-856, and strategic partnerships for development and commercialization. Potential catalysts include positive clinical trial data releases, regulatory approvals, and successful fundraising activities. However, risks include clinical trial failures, regulatory hurdles, competition from established therapies, and the need for additional capital to fund ongoing research and development.

Based on FMP financials and quantitative analysis

IMUX Key Highlights

• Immunic, Inc. is a clinical-stage biopharmaceutical company focused on oral therapies for autoimmune diseases.
• Lead program IMU-838 is in Phase 2 clinical trials for relapsing-remitting multiple sclerosis and inflammatory bowel disease.
• The company is also developing IMU-935, an inverse agonist of ROR?t, and IMU-856 for intestinal barrier restoration.
• Immunic is headquartered in New York, NY, with 91 employees.
• Market capitalization of $146.65M as of 2026-05-10.

Who Are IMUX's Competitors?

IMUX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMUX's Key Strengths?

• Pipeline of selective oral immunology therapies.
• Lead program IMU-838 in Phase 2 clinical trials.
• Experienced management team.
• Focus on convenient oral formulations.

What Are IMUX's Weaknesses?

• Clinical-stage company with no approved products.
• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• Competition from established pharmaceutical companies.

What Could Drive IMUX Stock Higher?

• Release of Phase 2 clinical trial data for IMU-838 in relapsing-remitting multiple sclerosis.
• Initiation of Phase 2 clinical trial for IMU-838 in inflammatory bowel disease.
• Advancement of IMU-935 and IMU-856 through preclinical and clinical development.
• Potential strategic partnerships and collaborations with pharmaceutical companies.

What Are the Key Risks for IMUX?

• Financial-distress signal — its Altman Z-Score of -3.32 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for IMU-838 or other pipeline candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established therapies and pharmaceutical companies.
• Need for additional capital to fund research and development.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for IMUX?

• Expansion of IMU-838 into New Indications: Immunic has the opportunity to expand the use of IMU-838 beyond relapsing-remitting multiple sclerosis and inflammatory bowel disease. Exploring its efficacy in other autoimmune conditions, such as rheumatoid arthritis or psoriasis, could significantly broaden its market potential. The market for rheumatoid arthritis therapeutics alone is projected to reach billions of dollars by 2030, offering a substantial growth avenue for Immunic if clinical trials demonstrate positive results.
• Advancement of IMU-935 and IMU-856: The successful development and commercialization of IMU-935 and IMU-856 represent significant growth opportunities for Immunic. IMU-935, as an inverse agonist of ROR?t, targets novel pathways in autoimmune diseases, potentially offering a differentiated therapeutic approach. IMU-856 aims to restore intestinal barrier function, addressing a critical need in conditions like IBD and IBS-D. Positive clinical data and regulatory approvals for these programs could drive substantial revenue growth.
• Strategic Partnerships and Collaborations: Immunic can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline. Partnering with larger pharmaceutical companies can provide access to funding, expertise, and established distribution networks. Collaborations with academic institutions and research organizations can enhance scientific understanding and accelerate drug discovery efforts. These partnerships can significantly de-risk the development process and expand Immunic's reach.
• Geographic Expansion: Immunic has the potential to expand its geographic footprint beyond its current focus. Targeting markets in Europe and Asia, where there is a growing demand for autoimmune disease therapies, can drive revenue growth. Adapting its clinical trial strategies and regulatory submissions to meet the requirements of different regions will be crucial for successful geographic expansion. This expansion could tap into new patient populations and increase overall market share.
• Orphan Drug Designations: Immunic can pursue orphan drug designations for its therapies targeting rare autoimmune diseases. Orphan drug designation provides several benefits, including market exclusivity, tax credits for clinical trial expenses, and waived or reduced regulatory fees. These incentives can significantly reduce the cost and risk associated with developing therapies for rare diseases, making it a more attractive investment opportunity. This strategy can lead to faster regulatory approval and commercialization.

What Opportunities Does IMUX Have?

• Expansion of IMU-838 into new indications.
• Advancement of IMU-935 and IMU-856.
• Strategic partnerships and collaborations.
• Geographic expansion into new markets.

What Threats Does IMUX Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from existing therapies.
• Need for additional capital.

What Are IMUX's Competitive Advantages?

• Proprietary oral formulations offer convenience over injectable therapies.
• Strong intellectual property protection for its pipeline of drug candidates.
• Clinical trial data demonstrating efficacy and safety.
• Experienced management team with expertise in drug development and commercialization.

What Does IMUX Do?

Immunic, Inc., founded with the goal of creating novel oral therapies for chronic inflammatory and autoimmune diseases, operates as a clinical-stage biopharmaceutical company. The company's primary focus is on developing a pipeline of selective oral immunology therapies designed to address unmet needs in the treatment of conditions such as relapsing-remitting multiple sclerosis (RRMS) and inflammatory bowel disease (IBD). Immunic's lead development program, IMU-838, is currently undergoing Phase 2 clinical trials for RRMS and IBD, as well as being explored as a potential treatment for coronavirus disease. In addition to IMU-838, Immunic is also advancing IMU-935, an inverse agonist of ROR?t, and IMU-856, which aims to restore intestinal barrier function in patients suffering from conditions like IBD, irritable bowel syndrome with diarrhea (IBS-D), and immune checkpoint inhibitor-induced colitis. The company's strategic focus on oral therapies provides a competitive advantage, offering patients a more convenient and potentially more tolerable treatment option compared to injectable or infused therapies. Immunic, Inc. is headquartered in New York, New York, and manages its research and development activities with a team of 91 employees.

What Products and Services Does IMUX Offer?

• Develops oral immunology therapies for chronic inflammatory and autoimmune diseases.
• Conducts Phase 2 clinical trials for IMU-838 in relapsing-remitting multiple sclerosis.
• Conducts Phase 2 clinical trials for IMU-838 in inflammatory bowel disease.
• Develops IMU-935 as an inverse agonist of ROR?t.
• Develops IMU-856 for restoration of intestinal barrier function.
• Targets diseases such as irritable bowel syndrome and immune checkpoint inhibitor-induced colitis.

How Does IMUX Make Money?

• Focuses on research and development of novel oral therapies.
• Out-licenses or co-develops therapies with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties.
• Secures funding through venture capital and public offerings.

What Industry Does IMUX Operate In?

Immunic, Inc. operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The market for autoimmune disease therapies is substantial, driven by increasing prevalence and unmet medical needs. Immunic's focus on oral therapies positions it favorably against competitors offering injectable or infused treatments. The competitive landscape includes major pharmaceutical companies and specialized biotech firms, all vying for market share in this expanding sector. The biotechnology industry is subject to stringent regulatory oversight and faces challenges related to clinical trial success and commercialization.

Who Are IMUX's Key Customers?

• Patients suffering from chronic inflammatory and autoimmune diseases.
• Pharmaceutical companies seeking to expand their product portfolios.
• Healthcare providers prescribing treatments for autoimmune conditions.
• Research institutions collaborating on drug development.

Net buyingInsider Activity

Over the past six months, Immunic, Inc. insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 1.3M shares acquired (about $15.7M) — insiders putting money in tends to read as conviction.

IMUX Valuation & Market Position

With a $146.65M market cap, Immunic, Inc. sits in the micro-cap segment of the market. Relative to its peer group, IMUX's quantitative score of 30/100 is below the peer average of 80/100.

Key Financial Metrics

Return on assets is -55.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -53.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Immunic, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.32 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Immunic, Inc. revenue of about $12.5M for fiscal 2026, with EPS near $-4.38. The estimate reflects 9 contributing analysts.

Company Profile

Immunic, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Daniel Vitt. IMUX has traded publicly since 2014.

IMUX Financials

IMUX Latest News

IMUX Analyst Consensus

IMUX MoonshotScore

Latest Immunic, Inc. Analysis

What Investors Ask About Immunic, Inc. (IMUX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources